Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study ( DINE )
Journal of the Peripheral Nervous System · 2025-03 · 30 (1)
DOI: 10.1111/jns.70011 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 05.03.2025. Verfasst von Umanath Adhikari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Objectives
There are currently no FDA‐approved disease‐modifying therapies for diabetic peripheral neuropathy (DPN). We evaluated the effect of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in Type 2 diabetes mellitus (T2DM) with DPN. Research Design and Methods In this prospective, open‐label, randomised, controlled study, 40 participants with DPN were randomised to receive add‐on 10 mg dapagliflozin OD (Group A) to existing oral antidiabetic drugs (OAD) ( n = 22) or continue OADs as a standard of care (Group B) ( n = 18). Participants underwent assessment of neuropathic symptoms and signs (MNSI), vibration perception threshold (VPT), corneal confocal microscopy (CCM) to quantify corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fibre length (CNFL) and skin biopsy to assess intraepidermal nerve fibre density (IENFD) and plasma markers of oxidative stress at randomisation and after 6 months.
Results
HbA1c decreased in Group A ( p = 0.002) and Group B ( p = 0.003), with no change in weight, body mass index (BMI) or lipids. Total MNSI increased in Group A ( p = 0.01) with no change in Group B ( p = 0.06). IENFD increased significantly in Group A ( p = 0.01) and Group B ( p = 0.01), while CNFD ( p = 0.002), CNBD ( p < 0.001) and CNFL ( p = 0.025) increased in Group A with no change in Group B. There was a significant increase in glutathione peroxidase ( p = 0.02) in Group A with no change in Group B, and a decrease in malondialdehyde in both groups ( p < 0.001).
Conclusions
In participants with T2DM and DPN, dapagliflozin was associated with small nerve fibre regeneration and improvement in markers of oxidative stress. Trial Registration: Clinical Trial Registry India, CRTI Reg. No (CTRI/2022/06/043236); ClinicalTrials.gov Identifier: NCT05162690
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar.
- Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Rayaz A Malik, Ashu Rastogi
Zitieren
APA
Adhikari, U., Gad, H., Chatterjee, D., Malhotra, C., Bhadada, S. K., Malik, R. A., & Rastogi, A. (2025). Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study ( DINE ). Journal of the Peripheral Nervous System, 30(1). https://doi.org/10.1111/jns.70011
Vancouver
Adhikari U, Gad H, Chatterjee D, Malhotra C, Bhadada SK, Malik RA, et al. Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study ( DINE ). Journal of the Peripheral Nervous System. 2025;30(1). doi:10.1111/jns.70011
BibTeX
@article{Adhikari2025,
author = {Adhikari, Umanath and Gad, Hoda and Chatterjee, Debajyoti and Malhotra, Chintan and Bhadada, Sanjay Kumar and Malik, Rayaz A and Rastogi, Ashu},
title = {Dapagliflozin for Small Nerve Fibre Regeneration in Diabetic Peripheral Neuropathy: A Randomised Controlled Study ( DINE )},
journal = {Journal of the Peripheral Nervous System},
year = {2025},
volume = {30},
number = {1},
doi = {10.1111/jns.70011}
}
EUVIMED